The evidence from transcriptome data showed that IFN-induced genes played a central role in the pathophysiology of SLE and PAH, indicating anti-IFNα therapy may be an effective treatment for SLE–PAH. The gene discussed is IFNA1; the disease is pulmonary arterial hypertension.